Federal Circuit Affirms PTAB's Obviousness Holding for Novartis's Dementia Drug Patents

Federal Circuit Affirms PTAB's Obviousness Holding for Novartis's Dementia Drug Patents


The Federal Circuit affirmed the PTAB's final written decisions holding that claims directed to Novartis's dementia drug compositions containing Exelon were obvious in Novartis AG v. Noven Pharm.



from Biotech News